LAA were obtained from 14 patients with known AF undergoing elective cardiac surgery including LAA removal at the University Hospital Zurich. LAA endocardial cells were isolated and pre-incubated with ticagrelor (10 -7 , 10 -6 , 10 -5 M) or clopidogrel active metabolite (CAM) (1.5 Â 10 -8 , 1.5 Â 10 -7 , 1.5 Â 10 -6 M) before stimulation with tumour necrosis factor-alpha (TNF-a) (10 ng/mL). Finally, TF and PAI-1 expression and activity were analysed. Ticagrelor, unlike CAM, concentration dependently decreased TNF-a-induced TF expression and TF activity in LAA endocardial cells. Further, ticagrelor, but not CAM reduced PAI-1 expression and enzyme activity in TNF-astimulated LAA endocardial cells. In contrast, TF pathway inhibitor (TFPI) remained unaffected by both dugs.
Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia affecting approximately 2% of the general population in developed countries. 1 It increases the risk of thromboembolic complications such as cardiogenic stroke as well as heart failure and all-cause mortality. 2 Oral anticoagulation is superior to dual or single antiplatelet therapy 3 and is considered standard therapy to reduce thromboembolic complications and mortality in AF patients. AF leads to thrombus formation in the left atrial appendage (LAA) due to a reduction in blood flow, endocardial activation, and hypercoagulability mediated through cytokines such as tumour necrosis factor-alpha (TNF-a). 4 We previously demonstrated that TNF-a-activated human LAA endocardial cells increase their levels of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) expression and activity, which may contribute to a higher thrombogenicity in left vs. right atrial appendages. 5 An increasing body of evidence is suggesting pleotropic effects of certain P2Y12 receptor antagonists; 6,7 indeed, ticagrelor was shown to inhibit the adenosine transporter equilibrative nucleoside transporter 1, 6,7 leading to increased plasma levels of adenosine. 8 In the current study, we investigated whether ticagrelor or clopidogrel active metabolite (CAM) affect the expression of 
Results
Ticagrelor, but not CAM, reduces TF expression and activity
Ticagrelor concentration dependently decreased TNF-a-induced TF expression in LAA endocardial cells ( Figure 1A) . The maximum effect amounted to 40% reduction in TF expression as compared with TNF-a stimulated cells. In contrast, CAM did not affect TF expression ( Figure 1B) . In line with protein expression, ticagrelor, but not CAM, reduced TF activity ( Figure 1C) . In contrast, endocardial protein expression of TFPI, the physiological antagonist of TF, was affected neither by ticagrelor nor CAM (see Supplementary material online, Figure S1 ).
Ticagrelor, unlike CAM, decreases PAI-1 expression and activity
Similar to TF, ticagrelor also reduced PAI-1 expression in TNF-astimulated LAA endocardial cells ( Figure 1D) . The maximum effect observed was a 67% reduction in PAI-1 expression as compared with TNF-a stimulated cells. In contrast, no effect on PAI-1 expression was observed with CAM ( Figure 1E) . Similarly, ticagrelor, but not CAM reduced enzymatic PAI-1 activity in LAA endocardial cells ( Figure 1F ).
Discussion
In this study, we demonstrate for the first time that ticagrelor, but not CAM, reduces TNF-a-induced TF and PAI-1 expression and activity in LAA endocardial cells isolated from patients with AF, hinting towards a possible local antithrombotic effect of ticagrelor at the cellular level.
Current treatment strategies for stroke prevention in patients with AF focus on inhibition of clot formation through interference with the coagulation cascade using vitamin K antagonists or nonvitamin K oral anticoagulants. 2, 9, 10 Antiplatelet therapy, even dual anti-platelet therapy using aspirin and clopidogrel, has been shown to be inferior to oral anticoagulation in stroke prevention in AF patients. 3, 11 Newer generation antiplatelet agents such as ticagrelor, however, have not been evaluated for this indication.
Our current findings unravel a putative additional property of ticagrelor via which thromboembolic complications may be reduced, i.e. by decreasing local thrombogenicity of LAA endocardial cells through the reduction of crucial prothrombotic mediators such as TF and PAI-1. An increasing body of evidence suggests pleiotropic effects of ticagrelor; 6, 7 indeed, it was shown to inhibit the adenosine transporter equilibrative nucleoside transporter 1, 6,7 thereby leading to increased adenosine plasma concentrations in cardiac patients. 8 The current results indicate the possibility of a local antithrombotic effect of ticagrelor in the LAA of AF patients. It currently remains unknown whether other anticoagulant drugs may have similar properties. A recent study reported that rivaroxaban, in contrast to dabigatran, reduced TF expression in endothelial cells. 12 However, these experiments were performed in human vein endothelial cells (instead of left atrial endocardial cells in our setting) and only reported changes in TF gene expression leaving out protein expression as well as enzyme activity. 12 Yet, these findings in congregate raise the possibility that local antithrombotic effects may be operative in the reduction of stroke risk observed with anticoagulants. Twenty to 30% of patients with AF suffer from comorbidities such as coronary artery disease requiring antiplatelet therapy. 2, 9 Optimal antithrombotic regimen in these patients is currently a matter of debate due to the high bleeding risk associated with combined anticoagulant and antiplatelet therapy. 9 While the role of new P2Y12
antagonists such as ticagrelor has not yet been addressed 9 and is subject of ongoing studies, 13 local antithrombotic mechanisms by ticagrelor in the LAA may be of particular interest (and value) in this specific patient population. Further studies are required to investigate whether the observed ex vivo effects of ticagrelor translate into improved patient outcome, including both thromboembolic as well as bleeding complications. In summary, our results indicate that ticagrelor reduces the expression and activity of local procoagulant proteins in LAA endocardial cells, which may contribute to a reduction of thromboembolic complications in patients with AF. Our findings may instigate further research investigating the clinical implications of these findings, particularly for patients with AF in need of concomitant antiplatelet therapy.
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